PLA filing for the white blood cell growth factor was completed on Dec. 28. Amgen is seeking to market Neupogen (G-CSF, or granulocyte colony stimulating factor) as an adjunct to chemotherapy in certain cancers, primarily small cell lung cancer. The PLA includes data on more than 700 cancer patients from eight clinical centers in the U.S. and Europe.
You may also be interested in...
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from the year so far.